Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PIK3CA |
| Variant | Q546X |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | PIK3CA Q546X indicates any PIK3CA missense mutation that results in replacement of the glutamine (Q) at amino acid 546 by a different amino acid. |
| Associated Drug Resistance | |
| Category Variants Paths |
PIK3CA mutant PIK3CA exon10 PIK3CA Q546X |
| Transcript | NM_006218.4 |
| gDNA | chr3:g.179218306_179218308 |
| cDNA | c.1636_1638 |
| Protein | p.Q546 |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_006218.4 | chr3:g.179218306_179218308 | c.1636_1638 | p.Q546 | RefSeq | GRCh38/hg38 |
| XM_006713658.4 | chr3:g.179218306_179218308 | c.1636_1638 | p.Q546 | RefSeq | GRCh38/hg38 |
| XM_011512894.2 | chr3:g.179218306_179218308 | c.1636_1638 | p.Q546 | RefSeq | GRCh38/hg38 |
| XM_006713658.5 | chr3:g.179218306_179218308 | c.1636_1638 | p.Q546 | RefSeq | GRCh38/hg38 |
| NM_006218.3 | chr3:g.179218306_179218308 | c.1636_1638 | p.Q546 | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA Q546X | endometrial adenocarcinoma | no benefit | Copanlisib | Case Reports/Case Series | Actionable | In a Phase II (NRG-GY008) trial, Aliqopa (copanlisib) was well tolerated but demonstrated limited efficacy, resulted in 1 stable disease and 1 progressive disease in 2 patients with endometrioid adenocarcinoma harboring PIK3CA Q546 mutations, and stable disease in a patient with serous endometrial adenocarcinoma harboring a PIK3CA Q546 mutation (PMID: 31934607). | 31934607 |